Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America

Volumn 26, Issue 3, 2012, Pages 589-605

  Thomas, Anish ^a   Rajan, Arun ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anaplastic lymphoma kinase translocation; Epidermal growth factor receptor; Non small cell lung cancer; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANTIBIOTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; KETOCONAZOLE; LAPATINIB; LOPERAMIDE; OMEPRAZOLE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RANITIDINE; RIFAMPICIN; UNINDEXED DRUG; VANDETANIB;

ACNE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MONITORING; DRUG POTENTIATION; DRUG WITHDRAWAL; EDEMA; ENZYME INHIBITION; GENE TRANSLOCATION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN TOXICITY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84859984610     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.02.001     Document Type: Review

References (97)

1. Goldstraw P., Crowley J., Chansky K., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2(8):706-714.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995, 311(7010):899-909.
4. Cancer Incidence-Surveillance, Epidemiology, and End Results (SEER) Registries Research Data. April 15, 2011. Available at: Accessed September 21, 2011. http://seer.cancer.gov.
5. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
6. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5(5):341-354.
7. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7(7):505-516.
8. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290(16):2149-2158.
9. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21(12):2237-2246. [corrected].
10. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004, 6(Suppl 1):S20-S23.
11. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22(5):777-784.
12. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22(5):785-794.
13. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25(12):1545-1552.
14. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(25):5892-5899.
15. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366(9496):1527-1537.
16. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
17. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
18. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
19. Lee DH, Han JY, Yu SY, et al. A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. Presented at World Conference on Lung Cancer. San Francisco (CA), July 31 to August 4, 2009.
20. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742.
21. Fukuoka M., Wu Y.L., Thongprasert S., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29(21):2866-2874.
22. Rosell R., Gervais R., Vergnenegre A., et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011, 29(Suppl). [abstract: 7503].
23. Takeda K., Hida T., Sato T., et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010, 28(5):753-760.
24. Gaafar R.M., Surmont V.F., Scagliotti G., et al. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). J Clin Oncol 2010, 28(Suppl):15s. [abstract 7518].
25. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529.
26. Miller V.A., O'Connor P., Soh C., et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(Suppl):18s. [abstract LBA8002].
27. Kabbinavar F.F., Miller V.A., Johnson B.E., et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(Suppl):15s. [abstract 7526].
28. Coudert B., Ciuleanu T., Park K., et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012, 23(2):388-394.
29. Kelly K., Chansky K., Gaspar L.E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26(15):2450-2456.
30. Rosell R., Moran T., Queralt C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
31. Sequist L.V., Martins R.G., Spigel D., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26(15):2442-2449.
32. Hirsch F.R., Varella-Garcia M., Bunn P.A., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24(31):5034-5042.
33. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
34. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
35. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101(36):13306-13311.
36. Jackman D.M., Miller V.A., Cioffredi L.A., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15(16):5267-5273.
37. Tarceva (erlotinib) [package insert]. South San Francisco, CA: Genentech. Available at: Accessed October 2, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl .pdf.
38. Iressa (gefitinib) [package insert]. Wilmington, DE: AstraZeneca. Available at: Accessed October 2, 2011. http://www1.astrazeneca-us.com/pi/iressa.pdf.
39. Lynch T.J., Kim E.S., Eaby B., et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007, 12(5):610-621.
40. Gridelli C., Maione P., Amoroso D., et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol Hematol 2008, 66(2):155-162.
41. Potthoff K., Hofheinz R., Hassel J.C., et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011, 22(3):524-535.
42. Lacouture M.E., Maitland M.L., Segaert S., et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010, 18(4):509-522.
43. Kudoh S., Kato H., Nishiwaki Y., et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008, 177(12):1348-1357.
44. Li J., Zhao M., He P., et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007, 13(12):3731-3737.
45. Riely G.J., Kris M.G., Zhao B., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13(17):5150-5155.
46. Chaft J.E., Oxnard G.R., Sima C.S., et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib. Clin Cancer Res 2011, 17(19):6298-6303.
47. Greulich H., Chen T.H., Feng W., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005, 2(11):e313.
48. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2(1):e17.
49. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-792.
50. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
51. Bean J., Brennan C., Shih J.Y., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104(52):20932-20937.
52. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
53. Gong Y., Yao E., Shen R., et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009, 4(10):e7273.
54. Sos M.L., Koker M., Weir B.A., et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009, 69(8):3256-3261.
55. Uramoto H., Iwata T., Onitsuka T., et al. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 2010, 30(7):2513-2517.
56. Engelman J.A., Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008, 18(1):73-79.
57. Rubin B.P., Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 2006, 86(10):981-986.
58. Ross H.J., Blumenschein G.R., Aisner J., et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010, 16(6):1938-1949.
59. Britten C.D. Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 2004, 3(10):1335-1342.
60. Engelman J.A., Zejnullahu K., Gale C.M., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67(24):11924-11932.
61. Gonzales A.J., Hook K.E., Althaus I.W., et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008, 7(7):1880-1889.
62. Boyer M.J., Blackhall F.H., Park K., et al. Efficacy and safety of PF299804 versus erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). J Clin Oncol 2010, 28(Suppl):18s. [abstract LBA7523].
63. Mok T., Spigel D.R., Park K., et al. Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(Suppl):15s. [abstract LBA7537].
64. Li D., Ambrogio L., Shimamura T., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27(34):4702-4711.
65. Ercan D., Zejnullahu K., Yonesaka K., et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29(16):2346-2356.
66. Rauh D., Sos M.L., Rode H.B., et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010, 70(3):868-874.
67. Haber D.A., Godin-Heymann N., LlIkus L., et al. The T790M " gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008, 7(4):874-879.
68. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
69. Koivunen J.P., Mermel C., Zejnullahu K., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14(13):4275-4283.
70. Takeuchi K., Choi Y.L., Soda M., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008, 14(20):6618-6624.
71. Mano H., Soda M., Takada S., et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008, 105(50):19893-19897.
72. Shaw A.T., Yeap B.Y., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
73. Rodig S.J., Mino-Kenudson M., Dacic S., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15(16):5216-5223.
74. Sasaki T., Rodig S.J., Chirieac L.R., et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46(10):1773-1780.
75. Christensen J.G., Zou H.Y., Arango M.E., et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6(12 Pt 1):3314-3322.
76. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
77. Camidge D.R., Bang Y., Kwak E.L., et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non small cell lung cancer (NSCLC). J Clin Oncol 2011, 29(Suppl). [abstract 2501].
78. Crinò L., Kim D., Riely G.J., et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011, 29(Suppl). [abstract 7514].
79. Shaw A.T., Yeap B.Y., Solomon B.J., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12(11):1004-1012.
80. Katayama R., Khan T.M., Benes C., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011, 108(18):7535-7540.
81. Sasaki T., Koivunen J., Ogino A., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71(18):6051-6060.
82. Choi Y.L., Soda M., Yamashita Y., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363(18):1734-1739.
83. Xalkori (crizotinib) [package insert]. San Diego (CA): Pfizer. Available at: Accessed October 2, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202570s000l tr.pdf.
84. Benedettini E., Sholl L.M., Peyton M., et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 2010, 177(1):415-423.
85. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7(6):504-516.
86. Salgia R., Cipriani N.A., Abidoye O.O., et al. MET as a target for treatment of chest tumors. Lung Cancer 2009, 63(2):169-179.
87. Schiller J.H., Akerley W.L., Brugger W., et al. Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(Suppl):18s. [abstract LBA7502].
88. Yasenchak C., Nackaerts K., Awada A., et al. Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC). EJC Suppl 2010, 8(7):126.
89. de Boer R.H., Arrieta O., Yang C.H., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, 29(8):1067-1074.
90. Natale R.B., Thongprasert S., Greco F.A., et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011, 29(8):1059-1066.
91. Herbst R.S., Sun Y., Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11(7):619-626.
92. Lee J., Hirsh V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010, 28(Suppl):15s. [abstract 7525].
93. Goss G.D., Arnold A., Shepherd F.A., et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 2010, 28(1):49-55.
94. Schiller J.H., Larson T., Ou S.H., et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009, 27(23):3836-3841.
95. Scagliotti G, Krzakowski M, Szczesna A, et al. Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study (LBA 6). 35th European Society for Medical Oncology (ESMO) Congress. Milan (Italy), October 8-12, 2010.
96. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011, 117(17):3889-3899.
97. Gerber D.E., Minna J.D. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010, 18(6):548-551.